The pharmaceutical giant Novo Nordisk announced the availability of 9,000 employees, equivalent to 11.5% of its workforce.

The Danish company Novo Nordisk has announced the layoff of 9,000 employees, following a restructuring aimed at generating annual savings of $1.26 billion. The company, which has become the most valuable in Europe due to demand for its medications, is facing increased competition that is affecting sales. The restructuring will also involve exceptional costs of 9 billion Danish crowns, but savings of 1 billion are expected in the fourth quarter. Novo's shares have dropped by 46% this year, and sales of weight loss medications could significantly increase in the next ten years.